Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
FibroBiologics, Inc. (FBLG)
NASDAQ:FBLG
RESEARCH TOOLSreports
Holding FBLG?
Track your performance easily
FBLG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.08 - $55.00
Previous Close$2.41
Volume85.03K
Average Volume (3M)406.83K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$7.83M
Total Debt (Recent Filing)$1.56M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Nov 12, 2024EPS Estimate
-$0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding34,659,125
10 Day Avg. Volume214,151
30 Day Avg. Volume406,831
Standard Deviation0.50
R-Squared0.02
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)28.00
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$13.33Price Target Upside412.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
FibroBiologics, Inc. News
PremiumCompany Announcements
FibroBiologics Reports Q3 2024 Financial ResultsPremiumCompany Announcements
FibroBiologics Announces Leadership Changes and New AppointmentsOwnership Overview
17.51% Insiders
1.72% Mutual Funds
2.43% Other Institutional Investors
73.09% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
FBLG FAQ
What was FibroBiologics, Inc.’s price range in the past 12 months?
FibroBiologics, Inc. lowest stock price was $1.08 and its highest was $55.00 in the past 12 months.
What is FibroBiologics, Inc.’s market cap?
Currently, no data Available
When is FibroBiologics, Inc.’s upcoming earnings report date?
FibroBiologics, Inc.’s upcoming earnings report date is Nov 12, 2024 which is 11 days ago.
How were FibroBiologics, Inc.’s earnings last quarter?
FibroBiologics, Inc. released its earnings results on May 14, 2024. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.27.
Is FibroBiologics, Inc. overvalued?
According to Wall Street analysts FibroBiologics, Inc.’s price is currently Undervalued.
Does FibroBiologics, Inc. pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
What is FibroBiologics, Inc.’s EPS estimate?
FibroBiologics, Inc.’s EPS estimate is -$0.07.
How many shares outstanding does FibroBiologics, Inc. have?
FibroBiologics, Inc. has 34,659,126 shares outstanding.
What happened to FibroBiologics, Inc.’s price movement after its last earnings report?
FibroBiologics, Inc. reported an EPS of -$0.27 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.839%.
Which hedge fund is a major shareholder of FibroBiologics, Inc.?
Among the largest hedge funds holding FibroBiologics, Inc.’s share is Fund Evaluation Group, LLC. It holds FibroBiologics, Inc.’s shares valued at N/A.
---
FibroBiologics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.33 (412.69% Upside)
$13.33 (412.69% Upside)
Blogger Sentiment
Bullish
FBLG Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Fundamentals
Return on Equity
-267.86%
Trailing 12-Months
Asset Growth
-21.28%
Trailing 12-Months
Company Description
FibroBiologics, Inc.
FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc.
---
FBLG Stock 12 Month Forecast
Average Price Target
$13.33
▲(412.69% Upside)
Technical Analysis
Best Analysts Covering FBLG
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-20.63%
reiterated a buy rating 10 days ago
Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -20.63% per trade.
---